The China antiepileptics drugs market stood at around $0.82 Bn in 2022 and is projected to reach $1.32 Bn in 2030 with a CAGR of 2.3% for the year 2022-2030. Valproic acid and Lamotrigine are the top selling antiepileptic drugs in China. The market is segmented by generation and by distribution channel. To get a detailed report, contact us at - info@insights10.com

1. China Antiepileptics Drugs
Market
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

2. This report presents a strategic analysis of China Antiepileptics Drugs
Market and a forecast for its development in the medium and long term. It
provides a comprehensive overview of the market value, dynamics,
segmentation, characteristics, main players, trends and insights, growth
and demand drivers, challenges & future outlook, etc. This is one of the
most comprehensive reports about the China Antiepileptics Drugs
Market, and offers unmatched value, accuracy, and expert insights

3. Table of
Contents
• Market Overview
• Growth Drivers & Restraints
• Market Segmentation
• Major Market Share
• Competitive Landscape
• Key Company Profiles
• Healthcare Policies & Regulatory Framework
• Factors Driving Future Growth
• Future Opportunities
• Conclusion

4. 4 A Sample Report on China Antiepileptics Drugs Market I Confidential
Table of Contents
1. China Antiepileptics drugs market overview………………..……..………………………………................................................................07
1.2 Market size and forecast
2. Market growth Drivers and restrains ….………………..……..……..……………………............................................................................09
2.1 Market growth drivers
2.1.1 Increasing incidence of neurological disorders
2.1.2 Rising geriatric population rates
2.1.3 Advancement in drug modification
2.1.4 Government support
2.2 Market growth restraints
2.2.1 Epilepsy medicine shortage
3. Market Segmentation………………….…………………………………………………………………….…………….……………………..……15
3.1 By generation
3.2 By Distribution channel
4. China Antiepileptics major products market share……………..……..……………………………….........................................................19
4.1 Market Analysis, Insights, and Forecast- By Major products

5. 5 A Sample Report on China Antiepileptics Drugs Market I Confidential
Table of Contents (continued)
5. China Antiepileptics Drugs Market Analysis: Top Selling Drugs……………………………………………………………………….……21
5.1 Valproic acid
5.2 Lamotrigine
5.3 Topiramate
5.4 Zonisamide
5.5 Levetiracetam
5.6 Clonazepam
6. Competitive Landscape…………………………………………………………………………………………………………………………...….24
6.1 Key Company By Revenue
7. Key Company Profiles (Company Overview, Product & Services, Strategies & Financials) ….………….………………..……..….....26
7.1 Eisai Co. Ltd.
7.2 Sanofi
7.3 Pfizer Inc.
7.4 GlaxoSmithkline plc.
7.5 G.W. Pharmaceuticals International AG Oy

6. 6 A Sample Report on China Antiepileptics Drugs Market I Confidential
Table of Contents (continued)
8. Access and Reimbursement Scenario………………………………………………………………………………………………………..……40
8.1 Policy Changes and Reimbursement Scenario in China Antiepileptic Drugs Market
9. Factors Driving Future Growth…………………...………………………………….…………………………………………………………...…42
9.1 Future opportunities
10. Conclusion………………………………………………………………………………………………………………………………..……….…..44

7. China Antiepileptics Drugs Market Analysis
1. Overview

8. 8 A Sample Report on Report Title I Confidential
1.1 China Antiepileptics Drugs Market- Market Size & Forecast Overview
▪ The China Antiepileptics Drug market size stood at around
$0.82 Bn in 2022 and is projected to reach $1.32 Bn by
2030, exhibiting a CAGR of 2.3% during the forecast period
▪ The prevalence of epilepsy in China is 7%, and the
prevalence of active epilepsy is 4.6%. In addition, there is a
large gap in the treatment of epilepsy, which is about 63%
▪ Based on this, it is estimated that the current epilepsy
number of patients is more than 9 million, of which more
than 6.4 million are patients with active epilepsy
▪ Advancement in drugs provide small effects on liver
metabolism that converts into a lower rate of side effects
further contributing to the growth of the Antiepileptic Drugs
Market
Key Analysis

9. China Antiepileptics Drugs Market Analysis
2. Growth Drivers and Growth Restraints

10. 10 A Sample Report on Report Title I Confidential
2.1 Market Growth Drivers
Impact
Increasing incidence
of neurological
disorders
Increasing
government support
Impact
Rising geriatric
population
Increasing R&D activities
and investments in
clinical trials
Growth
Drivers

11. 11 A Sample Report on Report Title I Confidential
2.1 Market Growth Drivers (continued)
2.1.1 Increasing incidence of neurological disorders
Sample
Worldwide Epilepsy is the most common neurological disorder, affecting people of all ages. And significant
transformation of lifestyle for the past two decades, the epidemiology and spectrum of neurological disorders are
potentially changing and imposing great challenges for neurologic practice in China
Sample

12. 12 A Sample Report on Report Title I Confidential
Market Growth Drivers (continued)
By 2019, there were 254 million older people aged 60 and over, and 176 million older people aged 65 and over. By
2040, an estimated 402 million people (28% of the total population) will be over the age of 60
Sample
2.1.2 Rising geriatric population
Sample

13. 13 A Sample Report on Report Title I Confidential
Market Growth Drivers (continued)
2.1.3 Increasing R&D activities and investments in clinical trials
Drug R&D moves forward and the development mechanism becomes innovative, drugs trends more diversified and
effective
In recent years, the percentage of public R&D investment in the TCM subsector reached 8%
Sample
Sample

14. 14 A Sample Report on Report Title I Confidential
Market Growth Drivers (continued)
2.1.4 Increasing Government Support
China’s overhaul of regulations is giving hopeful biopharma manufacturers more than a foot in the door
The reforms brought a fast-track approval process and a potential local-study waiver for products targeting rare
diseases or diseases with substantial unmet needs
Sample
Since then, China has witnessed exponential growth in new approvals, and a significant reduction in drug lag as
compared to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)

15. China Antiepileptics Drugs Market Analysis
3. Market Segmentation

16. 16 A Sample Report on Report Title I Confidential
China Antiepileptic Drugs Market Segmentation
By Generation
China Antiepileptic Drugs Market Segmentation
By Distribution Channel
First Generation
Second Generation
Hospital
Retail
Online
Third Generation

17. 17 A Sample Report on Report Title I Confidential
3.1 Market Segmentation: By Generation
China Antiepileptic Drugs By Generation 2021
▪ Based on the generation type, the market is segmented
into First (phenytoin (PHT), phenobarbital (PB),
carbamazepine (CBZ), valproic acid (VPA), zonisamide
(ZNS), and clobazam (CLB)), Second (ZNS)and Third
(lacosamide (LCM) and eslicarbazepine), respectively.
▪ Second generation drugs hold a major market share while
third generation drugs are penetrating in the market with
the full swing and proving beneficial for the treatment of
epilepsy
Key Insights
First Generation Second Generation Third Generation
Sample
Sample

18. 18 A Sample Report on Report Title I Confidential
3.2 Market Segmentation: By Generation
China Antiepileptic Drugs By Distribution Channel 2021
▪ The hospital pharmacies represent a dominant share in
the market and the growing number of hospitals with the
adequate reimbursement policies are some of the major
factors responsible for the higher proportion of epilepsy
patients treated by these facilities
▪ Retail pharmacies are anticipated to be the fastest
growing segment due to its easy accessibility.
Key Insights
Hospital Retail Online
Sample
Sample

19. China Antiepileptics Drugs Market Analysis
4. Major Products Market Share

20. 20 A Sample Report on Report Title I Confidential
4.1 Market Analysis, Insights and Forecast- By Major products
Key Insights
China Antiepileptic Market Share for Major Drugs
Sample
Valproic acid Lamotrigine Topiramate
Zonisamide Levetiracetam Clonazepam
Rufinamide
▪ valproic acid, zonisamide, rufinamide, lamotrigine,
levetiracetam , topiramate and clonazepam are
the top drugs used currently in market

21. China Antiepileptics Drugs Market Analysis
5. Top Selling Drugs

22. 22 A Sample Report on Report Title I Confidential
Top Selling Drugs / Treatments in China
5.1 Valproic acid
▪ Valproic acid (VPA), one of the most
common histone deacetylase
inhibitors (HDACIs), is known as an
anticonvulsant and mood-stabilizing
drug clinically . Gathering evidence
have manifested that VPA directly or
synergistically exerted anti-tumor
effects on various solid tumors
Sample
5.2 Lamotrigine
▪ Lamotrigine is used alone or with
other medications to prevent and
control seizures. It may also be used
to help prevent the extreme mood
swings of bipolar disorder in adults.
Lamotrigine is known as an
anticonvulsant or antiepileptic drug
Sample Sample
5.3 Topiramate
▪ Topiramate is a medicine used
to treat epilepsy. These are also
called anti-epileptic medicines. It
can also be taken to prevent
migraine. This medicine is only
available on prescription. It
comes as tablets or capsules

23. 23 A Sample Report on Report Title I Confidential
Top Selling Drugs / Treatments in China (continued)
5.4 Zonisamide
▪ Zonisamide, sold under the brand
name Zonegran, is a medication
used to treat the symptoms of
epilepsy and Parkinson's disease.
Chemically it is a sulfonamide
Sample
5.5 Levetiracetam
▪ Sales value of levetiracetam in the
Chinese market continued to rise
from 2016 to 2019. In 2020, the
COVID-19 outbreak prevented
Chinese healthcare facilities from
functioning properly
Sample Sample
5.6 Clonazepam
▪ Clonazepam, sold under the brand
Klonopin among others, is a
medication used to prevent and
treat seizures, panic disorder,
anxiety, and the movement
disorder known as akathisia

24. China Antiepileptics Drugs Market Analysis
6. Competitive Landscape

25. 25 A Sample Report on Report Title I Confidential
Competitive Landscape: Key Players Revenue (Current and Forecasted)
2021F 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Eisai Co. Ltd. $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Sanofi $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Pfizer Inc. $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
GlaxoSmithKline plc. $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
G.W. Pharmaceuticals $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Lundbeck $xx $xx $xx $xx $xx $xx $xx $xx $xx $xx
Major Market Revenue of Epilepsy Drugs Market ($Bn)

26. China Antiepileptics Drugs Market Analysis
7. Key Company Profiles

27. 27 A Sample Report on Report Title I Confidential
7.1 Eisai Co. Ltd.
Company Profile
▪ It is a Japanese company pharmaceutical company
headquartered in Tokyo, Japan. It has expertise in
neurology and oncology related drugs.
▪ In neurology area, discovered & developed antiepileptic
drug Fycompa®. In the oncology area, the company
discovered and developed anticancer agent Halaven that
has been approved for use in the treatment of breast cancer
in over 75 countries
Company Name: Eisai Co. Ltd.
Year of Establishment: 1941
Headquarter: Tokyo, Japan
Revenue: $5362 Million
Website: Eisai Co., Ltd.｜A human health care
company

28. 28 A Sample Report on Report Title I Confidential
1. Eisai Co. Ltd. (continued)
▪ The revenue of the company for year ending 2021 was $5362 million.
▪ It has some 10,000 employees among which 1500 are from research.
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

29. 29 A Sample Report on Report Title I Confidential
▪ It is a French multinational healthcare company
headquartered in Paris, France.
▪ Originally, the corporation was established in 1973 and
merged with Synthélabo in 1999 to form Sanofi-
Synthélabo. In 2004, Sanofi-Synthélabo merged with
Aventis and renamed to Sanofi-Aventis, which were each
the product of several previous mergers. It changed its
name back to Sanofi in May 2011.
Company Name: Sanofi
Year of Establishment: 1973
Headquarter: Paris, France
Revenue: $42687 Million
Website: Sanofi, an innovative global healthcare
company - Sanofi
Company Profile
7.2 Sanofi

30. 30 A Sample Report on Report Title I Confidential
Sanofi (continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

31. 31 A Sample Report on Report Title I Confidential
Company Name: Pfizer Inc.
Year of Establishment: 1849
Headquarter: New York, United States
Revenue: $81288 Million
Website: http://www.pfizer.com/
Company Profile
7.3 Pfizer Inc.
▪ Pfizer Inc is an American multinational pharmaceutical and
biotechnology corporation
▪ Pfizer develops and produces medicines and vaccines for
immunology, oncology, cardiology, endocrinology, and
neurology. The company has several blockbuster drugs or
products that each generate more than US$1 billion in
annual revenues

32. 32 A Sample Report on Report Title I Confidential
Pfizer Inc. (continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

33. 33 A Sample Report on Report Title I Confidential
Company Name: GlaxoSmithKline plc.
.
Year of Establishment: 2000
Headquarter: London, England
Revenue: $44992 Million
Website: Home | GSK
Company Profile
7.4 GlaxoSmithKline plc.
▪ GlacoSmithKline plc. is a British multinational
pharmaceutical corporation
▪ The company has a broad portfolio of innovative and
established medicines in respiratory, HIV, immuno-
inflammation and oncology. They are strengthening the R&D
pipeline through a focus on immunology, human genetics
and advanced technologies to help deliver transformational
new medicines for patients.

34. 34 A Sample Report on Report Title I Confidential
GlaxoSmithKline plc.(continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

35. 35 A Sample Report on Report Title I Confidential
Company Name: G.W. Pharmaceuticals
Year of Establishment: 1998
Headquarter: Cambridge, United Kingdom
Revenue: $527 Million
Website: Home | GW Pharmaceuticals, plc
Company Profile
5. G.W. Pharmaceuticals
▪ GW Pharmaceuticals is a British pharmaceutics company, a
subsidiary of Jazz Pharmaceuticals, known for its multiple
sclerosis treatment product nabiximols (brand name,
Sativex) which was the first natural cannabis plant derivative
to gain market approval in any country.
▪ Another cannabis-based product, Epidiolex, was approved
for treatment of epilepsy by the US Food and Drug
Administration in 2018.

36. 36 A Sample Report on Report Title I Confidential
G.W. Pharmaceuticals (continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

37. 37 A Sample Report on Report Title I Confidential
Company Name: Lundbeck
Year of Establishment: 1915
Headquarter: Copenhagen, Denmark
Revenue: 1,720 crores DKK
Website: http://www.lundbeck.com/
Company Profile
7.6 Lundbeck
▪ Lundbeck is a global pharmaceutical company highly
committed to improving the quality of life of people living
with brain diseases
▪ For more than 70 years, they have been at the forefront of
research within neuroscience. The key areas of focus are
depression, schizophrenia, Parkinson’s disease and
Alzheimer’s disease
▪ They have research centers in China and Denmark

38. 38 A Sample Report on Report Title I Confidential
6. Lundbeck (continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

39. 39 A Sample Report on Report Title I Confidential
Abbott Laboratories (continued)
Sample
Breakdown of net revenue by segment, 2022
Revenues ($Bn), 2021-2030F
Analysis
1 2 3 4
XX
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
$XX Bn

40. China Antiepileptics Drugs Market Analysis
8. Access and Reimbursement Scenario

41. 41 A Sample Report on Report Title I Confidential
Policy Changes and Reimbursement Scenario in China Antiepileptic
Drugs Market
Sample
▪ National Medical Products Administration (NMPA) (formerly China Food and Drug Administration or CFDA) approves antiepileptic
drugs
▪ The governing body for epilepsy control in China is the China Association Against Epilepsy under the leadership of government
▪ The accreditation procedures for SECs (Secondary-level Epilepsy Center), and PESF (Primary-level Epilepsy Service Facility) have
initiated in 2021 by the provincial level associations against epilepsy using the grading system set up by the CAAE
▪ Establishing a “Consortium of Epilepsy Centers” in China to promote coordination, collaboration, and information sharing among
TCECs ( Tertiary-level Epilepsy Center), with the aim of establishing a nationwide network of epilepsy centers with high-level
expertise in the diagnosis and treatment of epilepsy

42. China Antiepileptics Drugs Market Analysis
9. Factors Driving Future Growth

43. 43 A Sample Report on Report Title I Confidential
Future Opportunities
Active government support and investments to expedite market growth
Continuous research and development to meet the unmet needs to further propel the antiepileptics drugs market growth
Implementation of new strategies to revisit the antiepileptic drugs discovery and development
Sample
Sample

44. China Antiepileptics Drugs Market Analysis
10. Conclusion

45. Methodology & Scope

46. 46 A Sample Report on Report Title I Confidential
Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

47. 47 A Sample Report on Report Title I Confidential
Analysis Methodology
Our Analysis Methodology involves three critical stages:
Primary
Research
Secondary
Research
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Data Collection
Market Data Analysis
& Statistical Model
Interpretation &
Presentation

48. 48 A Sample Report on Report Title I Confidential
Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

49. 49 A Sample Report on Report Title I Confidential
Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2021 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

50. 2021
2022-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (5 working days) with
purchase. We will provide you with data that is
currently not a part of our scope as a part of
customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

51. The report is prepared
using a proven
methodology and insightful
research
Reliable
The data is prepared by a
team of highly qualified &
experienced research
analysts & vetted by our
local associates
Expert-verified
Allowing you to confidently
make smarter business and
strategic decisions
Real
Covers everything you
would need to know about
the market including
market size, competitive
analysis & much more
Comprehensive
You do not have to be a
market expert to
understand what really is
happening on the market
and how it works
Easy to read
What kind of Data is Presented
in this Report?
This report presents data, which is:
www.insights10.com

52. About

53. www.insights10.com
A large database of over 30,000 syndicated market
research reports in pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Lifesciences Market
Research Reports you
can trust

54. Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get Insights to take
informed Business
Decisions
www.insights10.com

55. Market Research Reports
across various domains of healthcare
Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices

56. Our
Services
1
2
3
4
5
6
10
9
8
7
Market Research Reports
Customized Reports
Primary Research
Database Services
Full-Time Engagement
Conference Coverage
Competitive Intelligence
Strategic Research Projects Regulatory Compliance
Report Subscription Services

57. Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis
www.insights10.com

58. Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players
www.insights10.com

59. Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

60. Mukesh is an engineering graduate
with an MBA in Marketing. He is a
seasoned healthcare market
research & marketing professional
with a progressive experience of over
20 years in Life Sciences, Pharma
and Medical Device sectors. With an
in-depth understanding of primary
research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare
& completed several research
projects across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Dhruv Joshi is an engineer and has done
Masters in Hospital Administration with
over 4 years of experience in the
healthcare and life science industry. He
has gained proficiency in market
research, market assessment, and
developing insights from it. He has
worked on various consulting projects
across different geographies including
Asia, Europe, US, MENA. He has been
aligned in working for sector reports of
various geographies along with market
sizing and forecasting.
Dr. Purav Gandhi
Founder & CEO
Mukesh Nayak
Head - Marketing
Ritu Baliya
Engagement Manager
Dhruv Joshi
Consultant
Project Leadership Team

61. 7 years of experience working with leading organizations in pharma, MedTech
and healthcare domain. Some of our recent clients are mentioned below
… and many more

62. Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.